Mobile website
Archive > Volume 23 Issue 6 > 2016,23(6):813-818. DOI:10.3872/j.issn.1007-385X.2016.06.013 Prev Next
Clinical Research
Curative efficacy analization of autologous tumor antigen loaded DC-CIK cytotherapy for the patients with gastric cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To explore the curative effect and safety of autologous tumor antigen loaded dendritic cells combined with cytokine-induced killer (DC-CIK) cells in the treatment of patients with gastric cancer. Methods: Two hundred seventy patients who received operative resection of gastric cancer in Fujian Provincial Cancer Hospital during January, 2005 to January, 2010 were retrospectively analyzed. Acording to wether receiving DC-CIK therapy, the patients were divided into DC-CIK treatment group (120 cases) and control group (150 cases). Flow cytometry assay was used to analyze phenotype of DC-CIK cells. Overall survival (OS) between both groups was compared. Advers reactions of the DC-CIK therapy were observed. And prognostic factors of the gastric cancer were analyzed by Cox regression model. Results: In the mature DC, the percentages of HLA-DR+, CD8+, CD83+ and CD86+ cells were（96.16±151）%, （96.58±2.66）%, （96.44±2.20）%, and （98.74±0.76）% respectively. In CIK cells. the proportions of CD3+，CD3+CD4+，CD3+CD8+ and CD3+CD16+/CD56+ cells were （91.98±5.9）%，（25.19±10.5）%，（71.15±7.8）% and （18.73±7.4）% respectively. The median OS was 77 months in the DC-CIK treatment group and compared to OS median of 51 months in the control group, the difference was significant (χ2＝4.431，P<0.05). DC-CIK therapy, adjuvant chemotherapy and TNM stage are independent prognostic factors for gastric cancer. Common adverse reactions are fever, chill and weakness in the DC-CIK therapy. Conclusion: Autologous tumor antigen-loaded DC-CIK therapy could prolong OS of patients with gastric cancer after operation of gastric cancer, and have little adverse reactions as well as be safety and effective.
Keywords:
Project Supported:
Project supported by the National Clinical Key Specialty Discipline Construction Program of China，the Key Clinical Specialty Discipline Construction Program of Fujian Province，and the Fujian Medical Innovation Project（No. 2015-CXB-4）
Clc Number:
